Six months of treatment with the endoscopic duodenal-jejunal bypass liner does not lead to decreased systemic inflammation in obese patients with type 2 diabetes.
In obese patients with type 2 diabetes, six months of treatment with endoscopic duodenal-jejunal bypass liner do not lead to decreased systemic inflammation.